Dell Technologies Inc. (NYSE: DELL): What EMC’s $984.3 m Air Force award means for defense IT strategy
Read More Pharma Industry News I-SPY 2 data puts Natera’s Signatera at the center of early breast cancer risk debates Natera’s I-SPY 2 data suggests ctDNA may finally align early breast cancer risk with treatment intensity. Read why this matters for payers and markets. byPallavi MadhirajuDecember 16, 2025